Clinical data show significant reductions in both pain and inflammation in RA and inflammatory bowel disease patients treated with sulfasalazine [36], an inhibitor of sepiapterin reductase [37] leading to reduced BH4 levels. This evidence concerns the gene SPR and inflammatory bowel disease.